PEMBROLIZUMAB
pembrolizumab 100 mg/4 mL injection, 4 mL vial
PEMBROLIZUMAB (12605K)
12605K
Manner of administration:Injection
Restriction
Indication: Unresectable or metastatic deficient mismatch repair (dMMR) colorectal cancer
Treatment phase: Initial treatment
Restriction
Indication: Unresectable or metastatic deficient mismatch repair (dMMR) colorectal cancer
Treatment phase: Continuing treatment
Quantities & Cost
| Max amount | # of repeats | DPMA | Max safety net | General Patient Charge |
|---|---|---|---|---|
| Max amount: 400 mg | # of repeats: 6 | DPMA: $14,870.58 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | ||||
| Keytruda
(pembrolizumab 100 mg/4 mL injection, 4 mL vial)
|
||||
